The semiconductor testing equipment leader capitalizes on surging AI chip demand to deliver historic Q3 results, while unveiling a significant treasury share cancellation and business segment reorganization aimed at enhancing shareholder value and operational focus.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
While speculative tech stories often capture headlines, Ashtead Technology Holdings (LON:AT.) presents a compelling case built on profitability and sustained growth. With EPS soaring 57% annually over three years and significant insider investment, the subsea equipment specialist is drawing attention from discerning investors.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
As AMETEK prepares to report its quarterly results, investors are watching to see if the electronics manufacturer can maintain its streak of strong performance amid a mixed landscape for industrial equipment firms.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
After a bruising year that saw its shares tumble by a third, biotech giant CSL is back in the spotlight. We delve beyond the headline numbers, examining valuation models and market sentiment to assess if the sell-off has created a compelling entry point for long-term investors.
Ichor Holdings (ICHR) shares have taken investors on a rollercoaster, soaring over 64% in a month before a sharp 9% single-day drop. With the semiconductor equipment maker posting revenue near $1 billion alongside net losses, the market is grappling with how to price its future in a cyclical industry. We examine whether the pullback presents a buying opportunity or a warning sign.
FTAI Aviation Ltd. has captivated investors with a staggering 167% surge, driven by explosive revenue growth and a unique hybrid model. But with a sky-high valuation, the market debates whether this aviation equipment leader is poised for a smooth cruise or facing turbulent air ahead.
The equipment rental giant's stock suffered its worst week in recent memory after quarterly results fell short of Wall Street's expectations, compounded by a price target cut from a major bank.
New data reveals tariffs imposed on key materials like steel and aluminum pushed nonresidential construction costs up 3.2% in 2025, with economists warning of continued pressure and broader impacts on equipment prices in the year ahead.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.
Yemen's Houthi rebels have seized telecommunications equipment and vehicles from multiple UN offices in Sana'a, the United Nations reported Friday, marking a significant escalation in restrictions that threatens to cripple humanitarian operations in the war-torn country.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
The United Nations has condemned the seizure of critical telecommunications equipment from its offices in Sanaa by Houthi forces, warning the move severely hampers humanitarian efforts for millions of Yemenis amid a worsening crisis.
Trimble expands its distribution network in key Midwestern markets by appointing West Side Tractor Sales Co. as a new authorized technology outlet and reseller, enhancing local access to its precision construction solutions for John Deere equipment users.
The Hotchkis & Wiley Global Value Fund credited Ericsson (ERIC) as a key driver of its fourth-quarter returns, as the telecom equipment maker's shares surged. The fund's latest investor letter details how strategic stock picks, particularly in non-U.S. markets, fueled its outperformance against a global benchmark.
